In English | En español

National Cancer Institute

at the National Institutes of Health

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI

Clinical Trials Search Results

Page Options

Email This Document

Clinical Trial Questions?
Get Help:
1-800-4-CANCER
LiveHelp online chat

Popular Resources

Help Using the NCI Clinical Trials Search Form
Learn About Clinical Trials
About NCI's List of Cancer Clinical Trials
NCI Dictionary of Cancer Terms
NCI Drug Dictionary

View Content for:

Patients
Health Professionals

Display:

Title
Description with: Locations Eligibility
Full Trial Description
Custom

Results 1-25 of 380 for your search:

Drug:  bevacizumab
Find trials that include:  Any drugs shown
Trial Status:  Active

Hide Search Criteria

Show Search Criteria

Help with Results

Select All on Page Sort by: Show Results per Page

A Study of Avastin With Taxane Therapy in Patients With Triple Negative Breast Cancer

Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ML22780, 2009-014279-37, NCT01094184

Study Comparing Optimized 5-FU Dosing and Standard Dosing in Metastatic Colorectal Cancer Patients Treated With mFOLFOX6

Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: PROFUSE-2011, NCT01468623

Correlation Between RECIST-conventional Imaging Techniques, Morphologic Response by CT- Histopathologic Response in Hepatic Metastasis Secondary to Colorectal Cancer

Phase: Phase IV
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: GEMCAD-1006, NCT01493713

An Extension Study to Provide Continued Avastin Therapy to Patients With Solid Tumours Who Were Previously Enrolled in a Roche/Genentech Sponsored Study

Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MO25757, 2011-002009-31, NCT01588184

A Translational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ASCENT)

Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ML25753, NCT01588990

Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Previously Untreated Stomach Cancer, Gastroesophageal Junction Cancer or Lower Oesophageal Cancer That Can Be Removed by Surgery

Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000536013, MRC-ST03, EU-20710, ISRCTN46020948, EUDRACT-2006-000811-12, CTA-00316/0221/001, NCT00450203

Mesothelioma Avastin Plus Pemetrexed-cisplatin Study

Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: IFCT-GFPC-0701, NCT00651456

Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer

Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: TG4010.14/TIME, 8559, NCT01383148

Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer

Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: GBG 66, 2011-000553-23, NCT01426880

10.

Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00509, U10CA021115, CDR0000475774, E1505, ECOG-E1505, SWOG-E1505, CALGB-E1505, CAN-NCIC-E1505, NCCTG-E1505, NCT00324805

11.

Adjuvant Xeloda Plus Eloxatin +/- Avastin After Radical Resection of Liver Metastasis of Colorectal Cancer

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: HEPATICA, NCT00394992

12.

5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC)

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: FIRE-3, NCT00433927

13.

A Study of Avastin (Bevacizumab) Plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MO19391, NCT00448591

14.

Carboplatin and Paclitaxel With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00587, U10CA027469, CDR0000546714, GOG-0213, NCT00565851

15.

Phase III Randomized Study of Carboplatin and Paclitaxel With Versus Without Bevacizumab in Patients With Newly Diagnosed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: MREC-ICON7, EUDRACT-2005-003929-22, ISRCTN91273375, ROCHE-MREC-ICON7, EU-20730, ICON7, MREC-06/MRE02/52, NCT00483782

16.

Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00507, U10CA021115, CDR0000582533, E1305, ECOG-E1305, NCT00588770

17.

FOLFOX-4 3months Versus 6 Months and Bevacizumab as Adjuvant Therapy for Patients With Stage II/III Colon Cancer

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2007-000354-31, NCT00646607

18.

Second-Line Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer Who Have Received First-Line Chemotherapy and Bevacizumab

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: CDR0000598567, GONO-BEBYP-ASL607LIOM03, GONO-AIFA - FARM5C4FB4, EUDRACT:2007-002886-11, GONO– ASL607LIOM03, EU-20860, NCT00720512

19.

Combination Chemotherapy and Bevacizumab as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: CDR0000598582, GONO-TRIBE, ASL608LIOM04, EUDRACT:2008-001537-10, TRIBE, EU-20859, NCT00719797

20.

A Study of Pemetrexed, Carboplatin and Bevacizumab in Patients With Nonsquamous Non-Small Cell Lung Cancer

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 9707, H3E-MC-JMHD, NCT00762034

21.

Phase III Study of Induction Therapy Comprising Bevacizumab, Irinotecan Hydrochloride, Fluorouracil, and Leucovorin Calcium (B-FOLFIRI) With Versus Without Capecitabine Followed By Bevacizumab Maintenance Therapy With or Without B-FOLFIRI Reinduction Therapy in Patients With Inoperable Previously Untreated Metastatic Colorectal Cancer

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: SICOG-0803, SICOG 0803, MARTHA, EudraCT-2008-004890-17, NCT00797485

22.

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20080259, NCT00911170

23.

A Study of Avastin (Bevacizumab) + Xeloda (Capecitabine)as Maintenance Therapy in Patients With HER2-Negative Metastatic Breast Cancer

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MO22223, 2008-006872-31, NCT00929240

24.

Phase III Randomized Study of Gemcitabine Hydrochloride and Cisplatin With Versus Without Bevacizumab in Patients With Advanced Transitional Cell Carcinoma of the Urinary Tract

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: CALGB-90601, CALGB-90601, NCT00942331

25.

Phase III Randomized Study of Carboplatin and Paclitaxel or Carboplatin, Paclitaxel, and Bevacizumab With Versus Without Concurrent Cetuximab in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: SWOG-S0819, S0819, NCT00946712

Select All on Page

Help with Results

We Can Answer Your Questions
1-800-4-CANCER
LiveHelp Online Chat

NCI Home
Contact Us
Policies
Accessibility
Viewing Files
FOIA
Site Help
Site Map

Other Versions of this Site: Mobile | Español

Follow Us:

Twitter
YouTube
Facebook
RSS

NIH…Turning Discovery Into Health^®